Skip to main content
BioSyent Inc. logo

BioSyent Inc. — Investor Relations & Filings

Ticker · RX ISIN · CA0906901081 TSXV Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2022-11-17 Regulatory Filings
Country CA Canada
Listing TSXV RX

About BioSyent Inc.

https://www.biosyent.com/

BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company focused on enhancing patient lives by addressing unmet medical needs. The company's primary business model involves sourcing, in-licensing, and acquiring innovative pharmaceutical and healthcare products globally for development and commercialization. BioSyent markets a diverse portfolio of products, including prescription, over-the-counter, and behind-the-counter options, primarily serving markets in Canada and select international regions.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Regulatory Filings
2022-11-17 English
Interim financial statements/report – English.pdf
Regulatory Filings
2022-11-17 English
News release - English.pdf
Regulatory Filings
2022-11-17 English
News release - English.pdf
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the scheduled date for BioSyent Inc.'s Q3 and YTD 2022 earnings release, specifying that the financial results will be reported on November 16, 2022. It does not contain actual financial data or detailed financial statements but rather informs about the upcoming earnings release and a presentation to be made available on that date. The document length is short (2265 characters), and it serves as an announcement rather than the earnings report itself. According to the classification rules, such announcements about the timing of earnings releases are best classified as Earnings Release (ER) announcements if they contain key highlights, or Report Publication Announcement (RPA) if they only announce the timing without financial data. Since this document only announces the date and availability of the earnings release and presentation without any financial results or highlights, it fits the Report Publication Announcement (RPA) category rather than the Earnings Release (ER) category.
2022-11-10 English
News release - English.pdf
Notice of Dividend Amount Classification · 100% confidence The document is a press release announcing that BioSyent Inc.'s Board of Directors has declared a quarterly dividend of $0.04 per common share, with payment and record dates specified. It focuses solely on the dividend declaration and payment details, without any financial statements or comprehensive financial data. The document length is short (2310 characters), and it does not contain an actual dividend report but rather an announcement of the dividend amount and payment schedule. Therefore, it fits the category of a Notice of Dividend Amount (DIV).
2022-10-12 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that BioSyent Inc. will present at the Virtual MicroCap Leadership Summit. It contains no financial statements, no detailed financial data, no regulatory filings, no voting results, no management changes, and no report attachments. The content is primarily an event announcement and investor outreach information. The document length is short (2479 characters), and it does not mention any report being attached or published. Therefore, it does not qualify as an Annual Report, Earnings Release, Investor Presentation, or any other detailed financial or regulatory filing. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2022-09-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.